Jane Street Group LLC Boosts Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Jane Street Group LLC grew its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 100.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 323,514 shares of the company’s stock after buying an additional 162,321 shares during the period. Jane Street Group LLC owned 0.45% of Zentalis Pharmaceuticals worth $980,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Northern Trust Corp boosted its stake in Zentalis Pharmaceuticals by 2.2% in the 4th quarter. Northern Trust Corp now owns 484,738 shares of the company’s stock worth $1,469,000 after purchasing an additional 10,513 shares in the last quarter. Quarry LP grew its holdings in shares of Zentalis Pharmaceuticals by 256.7% during the fourth quarter. Quarry LP now owns 53,500 shares of the company’s stock worth $162,000 after buying an additional 38,500 shares in the last quarter. Oxford Asset Management LLP purchased a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth $52,000. Virtus ETF Advisers LLC boosted its position in shares of Zentalis Pharmaceuticals by 134.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 22,713 shares of the company’s stock valued at $69,000 after acquiring an additional 13,030 shares during the last quarter. Finally, Voya Investment Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 14.1% during the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock valued at $173,000 after acquiring an additional 7,058 shares during the last quarter.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $1.24 on Friday. Zentalis Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $13.00. The company has a market cap of $89.22 million, a P/E ratio of -0.50 and a beta of 1.81. The business has a fifty day moving average of $1.39 and a two-hundred day moving average of $2.28.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts’ consensus estimates of ($0.67). Sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers purchased 21,000 shares of the stock in a transaction on Wednesday, April 30th. The stock was bought at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now directly owns 281,192 shares of the company’s stock, valued at $393,668.80. This represents a 8.07% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 1.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have commented on ZNTL. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Finally, UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.